News | May 05, 2026
SK Capital sells Noramco assets to Siegfried
Keeps Halo Pharma to drive independent growth
Keeps Halo Pharma to drive independent growth
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
The new facility significantly increases Siegfried’s R&D capacity to drive development excellence and further growth
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
The new site enables end-to-end production of viral vector gene therapies
Subscribe To Our Newsletter & Stay Updated
